September 30, 2011 — Boston Scientific Corp. said the U.S. Court of Appeals for the Federal Circuit found in favor of the company in a 1998 stent patent infringement suit involving Johnson & Johnson.
In the decision, handed down Sept. 28, the Court of Appeals affirmed the U.S. District Court for the District of Delaware decision finding Boston Scientific's NIR Stent did not infringe Johnson & Johnson's Fischell patent.
"We are pleased with the decision and will continue to manage our litigation risks as part of our continuing effort to reduce our exposure," said Tim Pratt, executive vice president, chief administrative officer and general counsel for Boston Scientific.
For more information: www.bostonscientific.com